An introduction to pancreatic adenocarcinoma genetics, pathology and therapy

Cancer Biology and Therapy

Volumn 1, Issue 6, 2002, Pages 607-613

  Kern, Scott E ^a   Hruban, Ralph H ^a   Hidalgo, Manuel ^a   Yeo, Charles J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

BRCA2 mutations; Cancer precursors; Familial cancer; Genetic mutations; Mitomycin C; Pancreatic cancer; Pancreaticoduodenectomy; Telomeres

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUTATION; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; REVIEW;

ADENOCARCINOMA; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038650956     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.307     Document Type: Review

References (93)

1. Soh TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of hte pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-79.
2. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998; 227:821-31. (Pubitemid 29119529)
3. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998; 67:151-9. (Pubitemid 28134402)
4. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995; 221:43-9.
5. Gordon TA, Bowman HM, Tielsch JM, Bass EB, Burleyson GP, Cameron JL. Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg 1998; 228:71-8. (Pubitemid 30190318)
6. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222:638-45.
7. Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165:294-300. (Pubitemid 26425400)
8. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37. (Pubitemid 34984604)
9. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. (Pubitemid 27251144)
10. Heinemann V. Present and future treatment of pancreatic cancer. Semin Oncol 2002; 29:23-31.
11. Hulst SPL. Zur kenntnis der Genese des Adenokarzinoms und Karzinoms des Pankreas. Trans. T. van Heek and V. Koopman. Virchows Arch B 1905;180:288-316.
12. Sommers S, Murphy SA, Warren S. Pancreatic duct hyperplasia and cancer. Gastroenterol 1954; 27:629-640.
13. Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979; 43:1418-1428. (Pubitemid 9180309)
14. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976; 36:2690-2698.
15. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Goodman SN, Kern SE, et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25:579-586. (Pubitemid 32423354)
16. Kern SE. Advances from genetic clues in pancreatic cancer. Curr Opin Onc 1998; 10:74-80. (Pubitemid 28039245)
17. Hruban RH, Wilentz R, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156:1821-1825. (Pubitemid 30641750)
18. Gold EB. Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am 1995; 75:819-43.
19. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 1830-7. (Pubitemid 29389642)
20. Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H, et al. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999; 18:1073-80. (Pubitemid 29086285)
21. Iacobuzio-Donahue CA, Ryu B, R.H. H, Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002; 160:91-99. (Pubitemid 34052270)
22. Goggins M, Offerhaus GJA, Hilgers W, Griffin CA, Shekher M, Tang D, et al. Adenocarcinomas of the pancreas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998; 152:1501-1507. (Pubitemid 28275008)
23. Wilentz RE, Goggins M, Redston M, Marcus VA, Sohn TA, Yeo CJ, et al. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. Am J Pathol 2000; 156:1641-1651. (Pubitemid 30646702)
24. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001; 61:3139-44. (Pubitemid 32691966)
25. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001; 159:1619-27. (Pubitemid 33062504)
26. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002; 160:953-62. (Pubitemid 34224584)
27. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002; 160:1361-9. (Pubitemid 34411640)
28. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-554.
29. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics 1994; 8:27-31.
30. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57:3126-30. (Pubitemid 27351723)
31. Pellegata S, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54:1556-60. (Pubitemid 24106422)
32. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33. (Pubitemid 24187791)
33. Rozenblum E, Schutte M, Goggins M, Hahn SA, Lu J, Panzer S, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-4. (Pubitemid 27199667)
34. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science 1996; 271:350-3.
35. Jones JB, Song JJ, Hempen PM, Parmigiani G, Hruban RH, Kern SE. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res 2001; 61:1299-304.
36. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, et al. Allelotype of pancreatic adenocarcinoma using a xenograft model. Cancer Res 1995; 55:4670-5.
37. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the TGF beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58:5329-32. (Pubitemid 28551110)
38. Teng DH-F, Perry III WL, Hogan JK, Baumgard M, Bell R, Berry S, et al. Human mitogen- activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57:4177-82. (Pubitemid 27413418)
39. Su GH, Hilgers W, Shekher M, Tang D, Yeo CJ, Hruban RH, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. Cancer Res 1998; 58:2339-42. (Pubitemid 28252690)
40. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992; 7:1503-11.
41. Su GH, Bansal R, Montgomery E, Yeo CJ, Hruban RH, Kern SE. ACVR1B (ALK4) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA 2001; 98:3254-7. (Pubitemid 32220832)
42. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300-3. (Pubitemid 30132203)
43. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998; 21:81-6. (Pubitemid 28122842)
44. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenecity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-41. (Pubitemid 26127592)
45. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Buchler M, et al. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-MYB as a candidate oncogene. Cancer Res 1997;57:3135-9. (Pubitemid 27351725)
46. Ghadimi BM, Schröck E, Walker RL, Wangsa D, Jauho A, Meltzer PS, et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999;154:525-36. (Pubitemid 29094102)
47. Heidenblad M, Jonson T, Mahlamaki EH, Gorunova L, Karhu R, Johansson B, et al. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 2002; 34:211-23. (Pubitemid 34578678)
48. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161:1541-7. (Pubitemid 35265514)
49. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002;21:619-26.
50. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-3573. (Pubitemid 24225985)
51. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3. (Pubitemid 27247028)
52. Digiuseppe JA, Hruban RH, Goodman SN, Polyak M, van den Berg FM, Allison DC, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Amer J Clin Pathol 1994;101:684-8.
53. Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, et al. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43. (Pubitemid 30644436)
54. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60:2002-5.
55. Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-75. (Pubitemid 26120245)
56. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J 2001;7:266-73.
57. Tersmette AC, Petersen GM, Offerhaus GJA, Falatko FC, Goggins M, Rozenblum E, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clinical Cancer Res 2000;7:738-744.
58. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-4. (Pubitemid 27011364)
59. Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997;16:17-8.
60. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-93. (Pubitemid 34728862)
61. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991;6:127-31.
62. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-4.
63. Lynch HT, Brand RE, Lynch JF, Fusaro RM, Smyrk TC, Goggins M, et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000; 119:1756-60. (Pubitemid 32198701)
64. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987;316:1511-4. (Pubitemid 17076235)
65. Su GH, Hruban RH, Bova GS, Goggins M, Bansal RK, Tang DT, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-40. (Pubitemid 29262866)
66. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53. (Pubitemid 32198669)
67. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985;52:271-273. (Pubitemid 15229364)
68. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genet 1996; 14:141-5. (Pubitemid 26338792)
69. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Jr., Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. Journal of the National Cancer Institute 1997;89:442-6. (Pubitemid 27136736)
70. Wallrapp C, Gress TM. Isolation of differentially expressed genes by representational difference analysis. Methods Mol Biol 2001;175:279-94.
71. Wallrapp C, Muller-Pillasch F, Micha A, Wenger C, Geng M, Solinas-Toldo S, et al. Novel technology for detection of genomic and transcriptional alterations in pancreatic cancer. Ann Oncol 1999;10 Suppl 4:64-8.
72. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-26. (Pubitemid 34126959)
73. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49. (Pubitemid 34411628)
74. Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: Serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001;61:1833-8. (Pubitemid 32691994)
75. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan S, Leach SB, et al. Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4.
76. Argani P, Iacobuzio-Donahue CA, Ryu R, Goggins M, Rosty C, Wilentz RE, et al. Mesothelin is expressed in the vast majority of adenocarcinomas of the pancreas: Identification of a new cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
77. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993;24:1127-34. (Pubitemid 23306246)
78. Day JD, DiGiuseppe JA, Yeo CJ, Lai-Goldman M, Anderson SM, Kern SE, et al. Immunohistochemical evaluation of Her-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human Pathol 1996;27:119-24. (Pubitemid 26049464)
79. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41. (Pubitemid 28108791)
80. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27. (Pubitemid 29045184)
81. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
82. Hahn SA, Hoque ATMS, Moskaluk CA, daCosta LT, Schutte M, Rozenblum E, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996; 56:490-4.
83. Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000; 14:1400-6. (Pubitemid 30397083)
84. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297:606-9. (Pubitemid 34815345)
85. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001; 61:4842-50. (Pubitemid 32691900)
86. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. Embo J 2001; 20:4704-16. (Pubitemid 32848624)
87. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 1998; 2:159-66. (Pubitemid 128432028)
88. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998; 45:2020-6. (Pubitemid 29055770)
89. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am J Clin Oncol 1999; 22:187-90. (Pubitemid 30263351)
90. Miura T, Endo Y, Matumoto Y, Ikeda H. [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis - a case of 16 years survival]. Gan To Kagaku Ryoho 2000; 27:1794-800.
91. Vaughn C, Chapman J, Chinn B, Ward D, Groshko G, Maniscalco B, et al. Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. Am J Clin Oncol 1989; 12:49-52. (Pubitemid 19037252)
92. Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74:243-8.
93. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001; 61:4923-32. (Pubitemid 32694386)